Werewolf Historical Balance Sheet

HOWL Stock

USD 1.07 0.04 3.88%

Trend analysis of Werewolf Therapeutics balance sheet accounts such as Other Current Liabilities of 8 M or Total Current Liabilities of 14.3 M provides information on Werewolf Therapeutics' total assets, liabilities, and equity, which is the actual value of Werewolf Therapeutics to its prevalent stockholders. By breaking down trends over time using Werewolf Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Werewolf Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Werewolf Therapeutics is a good buy for the upcoming year.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

About Werewolf Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Werewolf Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Werewolf Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Werewolf Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Werewolf currently owns. An asset can also be divided into two categories, current and non-current.

Werewolf Therapeutics Balance Sheet Chart

At this time, Werewolf Therapeutics' Non Current Assets Total are quite stable compared to the past year. Cash And Short Term Investments is expected to rise to about 118 M this year, although the value of Total Current Liabilities will most likely fall to about 14.3 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Werewolf Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Werewolf Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Werewolf Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Werewolf Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Werewolf Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Werewolf Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.At this time, Werewolf Therapeutics' Non Current Assets Total are quite stable compared to the past year. Cash And Short Term Investments is expected to rise to about 118 M this year, although the value of Total Current Liabilities will most likely fall to about 14.3 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	14.7M	51.9M	11.0M	18.1M
Total Assets	160.2M	174.8M	126.9M	139.2M

Short Long Term Debt Total Total Assets

Werewolf Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.74	0.94	0.92	0.92	-0.96	0.91	0.95	-0.96	-0.9	0.76	1.0	0.88	0.5	0.43	1.0	0.69	0.47	-0.14	0.94	0.79	0.93	0.1	0.92	0.67	1.0
Short Long Term Debt Total	0.74		0.66	0.74	0.72	-0.63	0.69	0.72	-0.54	-0.71	0.41	0.69	0.96	0.94	0.11	0.69	0.62	0.47	-0.2	0.7	0.49	0.74	-0.01	0.78	0.78	0.69
Other Current Liab	0.94	0.66		0.98	0.9	-0.92	0.92	0.95	-0.91	-0.95	0.81	0.93	0.83	0.41	0.55	0.93	0.86	0.62	-0.25	0.93	0.66	0.97	0.0	0.91	0.77	0.93
Total Current Liabilities	0.92	0.74	0.98		0.89	-0.87	0.89	0.95	-0.84	-0.92	0.68	0.89	0.89	0.52	0.61	0.89	0.85	0.54	-0.29	0.92	0.65	0.94	-0.03	0.91	0.78	0.9
Total Stockholder Equity	0.92	0.72	0.9	0.89		-0.78	0.96	0.99	-0.85	-0.87	0.72	0.9	0.87	0.46	0.49	0.9	0.67	0.41	-0.52	0.99	0.86	0.95	-0.3	0.99	0.62	0.9
Other Liab	-0.96	-0.63	-0.92	-0.87	-0.78		-0.82	-0.84	0.97	0.87	-0.79	-0.97	-0.76	-0.4	-0.37	-0.97	-0.69	-0.54	-0.09	-0.83	-0.65	-0.86	-0.33	-0.8	-0.66	-0.97
Net Tangible Assets	0.91	0.69	0.92	0.89	0.96	-0.82		0.96	-0.86	-0.96	0.84	0.89	0.85	0.41	0.37	0.89	0.75	0.61	-0.47	0.97	0.71	0.97	-0.25	0.97	0.73	0.9
Property Plant And Equipment Net	0.95	0.72	0.95	0.95	0.99	-0.84	0.96		-0.89	-0.91	0.74	0.93	0.88	0.46	0.56	0.93	0.74	0.46	-0.44	1.0	0.82	0.97	-0.21	0.98	0.67	0.93
Net Debt	-0.96	-0.54	-0.91	-0.84	-0.85	0.97	-0.86	-0.89		0.85	-0.81	-0.98	-0.72	-0.26	-0.44	-0.98	-0.6	-0.43	0.06	-0.89	-0.78	-0.87	-0.16	-0.84	-0.53	-0.98
Retained Earnings	-0.9	-0.71	-0.95	-0.92	-0.87	0.87	-0.96	-0.91	0.85		-0.87	-0.88	-0.84	-0.46	-0.32	-0.88	-0.86	-0.76	0.3	-0.9	-0.55	-0.97	0.07	-0.91	-0.85	-0.88
Accounts Payable	0.76	0.41	0.81	0.68	0.72	-0.79	0.84	0.74	-0.81	-0.87		0.79	0.57	0.19	0.11	0.79	0.75	0.79	-0.18	0.75	0.5	0.85	0.0	0.75	0.7	0.77
Cash	1.0	0.69	0.93	0.89	0.9	-0.97	0.89	0.93	-0.98	-0.88	0.79		0.83	0.44	0.41	1.0	0.66	0.47	-0.1	0.92	0.79	0.91	0.14	0.9	0.63	1.0
Non Current Assets Total	0.88	0.96	0.83	0.89	0.87	-0.76	0.85	0.88	-0.72	-0.84	0.57	0.83		0.81	0.32	0.83	0.72	0.5	-0.3	0.87	0.65	0.88	-0.08	0.92	0.8	0.84
Non Currrent Assets Other	0.5	0.94	0.41	0.52	0.46	-0.4	0.41	0.46	-0.26	-0.46	0.19	0.44	0.81		-0.05	0.44	0.5	0.39	-0.05	0.42	0.25	0.5	0.09	0.55	0.7	0.44
Other Assets	0.43	0.11	0.55	0.61	0.49	-0.37	0.37	0.56	-0.44	-0.32	0.11	0.41	0.32	-0.05		0.41	0.38	-0.15	-0.33	0.52	0.52	0.42	-0.17	0.42	0.11	0.44
Cash And Short Term Investments	1.0	0.69	0.93	0.89	0.9	-0.97	0.89	0.93	-0.98	-0.88	0.79	1.0	0.83	0.44	0.41		0.66	0.47	-0.1	0.92	0.79	0.91	0.14	0.9	0.63	1.0
Common Stock Total Equity	0.69	0.62	0.86	0.85	0.67	-0.69	0.75	0.74	-0.6	-0.86	0.75	0.66	0.72	0.5	0.38	0.66		0.84	-0.24	0.7	0.29	0.85	-0.02	0.73	0.94	0.67
Common Stock Shares Outstanding	0.47	0.47	0.62	0.54	0.41	-0.54	0.61	0.46	-0.43	-0.76	0.79	0.47	0.5	0.39	-0.15	0.47	0.84		-0.07	0.44	-0.02	0.66	0.06	0.51	0.89	0.46
Non Current Liabilities Total	-0.14	-0.2	-0.25	-0.29	-0.52	-0.09	-0.47	-0.44	0.06	0.3	-0.18	-0.1	-0.3	-0.05	-0.33	-0.1	-0.24	-0.07		-0.46	-0.37	-0.39	0.97	-0.48	-0.17	-0.11
Capital Lease Obligations	0.94	0.7	0.93	0.92	0.99	-0.83	0.97	1.0	-0.89	-0.9	0.75	0.92	0.87	0.42	0.52	0.92	0.7	0.44	-0.46		0.84	0.96	-0.24	0.99	0.64	0.93
Other Current Assets	0.79	0.49	0.66	0.65	0.86	-0.65	0.71	0.82	-0.78	-0.55	0.5	0.79	0.65	0.25	0.52	0.79	0.29	-0.02	-0.37	0.84		0.7	-0.21	0.81	0.21	0.8
Other Stockholder Equity	0.93	0.74	0.97	0.94	0.95	-0.86	0.97	0.97	-0.87	-0.97	0.85	0.91	0.88	0.5	0.42	0.91	0.85	0.66	-0.39	0.96	0.7		-0.15	0.97	0.81	0.92
Total Liab	0.1	-0.01	0.0	-0.03	-0.3	-0.33	-0.25	-0.21	-0.16	0.07	0.0	0.14	-0.08	0.09	-0.17	0.14	-0.02	0.06	0.97	-0.24	-0.21	-0.15		-0.26	0.03	0.13
Net Invested Capital	0.92	0.78	0.91	0.91	0.99	-0.8	0.97	0.98	-0.84	-0.91	0.75	0.9	0.92	0.55	0.42	0.9	0.73	0.51	-0.48	0.99	0.81	0.97	-0.26		0.72	0.9
Property Plant And Equipment Gross	0.67	0.78	0.77	0.78	0.62	-0.66	0.73	0.67	-0.53	-0.85	0.7	0.63	0.8	0.7	0.11	0.63	0.94	0.89	-0.17	0.64	0.21	0.81	0.03	0.72		0.63
Total Current Assets	1.0	0.69	0.93	0.9	0.9	-0.97	0.9	0.93	-0.98	-0.88	0.77	1.0	0.84	0.44	0.44	1.0	0.67	0.46	-0.11	0.93	0.8	0.92	0.13	0.9	0.63

Click cells to compare fundamentals

Werewolf Therapeutics Account Relationship Matchups

Werewolf Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	96.4M	179.3M	160.2M	174.8M	126.9M	139.2M
Short Long Term Debt Total	2.5M	15.7M	14.7M	51.9M	11.0M	18.1M
Other Current Liab	3.6M	7.7M	12.1M	8.9M	10.6M	8.0M
Total Current Liabilities	5.3M	11.9M	24.0M	19.4M	15.2M	14.3M
Total Stockholder Equity	(51.9M)	152.8M	122.3M	111.4M	73.4M	70.3M
Property Plant And Equipment Net	3.1M	16.3M	17.5M	14.8M	12.3M	12.4M
Net Debt	(90.0M)	(141.9M)	(114.6M)	(82.4M)	(101.2M)	(106.3M)
Retained Earnings	(51.9M)	(252.9M)	(306.7M)	(344.1M)	(414.6M)	(393.9M)
Accounts Payable	1.0M	2.0M	1.2M	1.3M	3.0M	1.7M
Cash	92.6M	157.5M	129.3M	134.3M	112.2M	118.0M
Non Current Assets Total	3.5M	18.2M	20.0M	36.5M	13.9M	17.5M
Non Currrent Assets Other	155K	649K	1.4M	21.6M	1.5M	1.5M
Other Assets	362K	1.9M	10.9M	1.0	1.15	1.09
Cash And Short Term Investments	92.6M	157.5M	129.3M	134.3M	112.2M	118.0M
Liabilities And Stockholders Equity	96.4M	179.3M	160.2M	174.8M	126.9M	139.2M
Non Current Liabilities Total	143.0M	14.6M	13.9M	44.1M	38.4M	39.7M
Capital Lease Obligations	2.5M	15.7M	14.7M	12.6M	11.0M	10.9M
Other Current Assets	688K	7.1M	4.0M	2.7M	851K	808.5K
Other Stockholder Equity	2K	405.7M	429.0M	455.4M	488.0M	326.0M
Total Liab	148.3M	26.5M	37.9M	63.5M	53.5M	50.1M
Net Invested Capital	(51.9M)	152.8M	122.3M	150.7M	99.5M	82.3M
Property Plant And Equipment Gross	3.1M	2.9M	9.0M	18.0M	17.3M	9.9M
Total Current Assets	92.9M	161.1M	140.2M	138.4M	113.1M	121.7M
Net Working Capital	87.6M	149.2M	116.2M	119.0M	97.9M	107.4M
Short Term Debt	677K	2.1M	4.2M	8.3M	1.6M	1.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:

How To Invest In Werewolf

Details

Is Werewolf Stock a good investment?

Details

What is Werewolf Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.69)

Revenue Per Share

0.044

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.30)

Return On Equity

(0.76)

The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Werewolf Historical Balance Sheet

About Werewolf Balance Sheet Analysis

Werewolf Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Werewolf Therapeutics balance sheet Correlations

Werewolf Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Werewolf Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings
Total Current Assets	- 0.97	Other Liab
Cash And Short Term Investments	- 0.97	Other Liab